Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists.
Klotz
Laurence
L
Department of Surgery, University of Toronto and the Division of Urology, Sunnybrook Health Sciences Centre, Toronto, Ont.